XPARMEDCL
Market cap509mUSD
Dec 24, Last price
16.76EUR
1D
0.00%
1Q
6.21%
IPO
131.17%
Name
Medincell SA
Chart & Performance
P/E
—
P/S
41.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.49%
Rev. gr., 5y
52.61%
Revenues
12m
+20.79%
Net income
-25m
L-21.78%
CFO
-12m
L-53.10%
Earnings
Sep 12, 2025
Profile
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 11,945 20.79% | 9,889 141.78% | 4,090 -50.04% | ||||||
Cost of revenue | 35,653 | 32,616 | 26,678 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (23,708) | (22,727) | (22,588) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 88 | (3,766) | (4,247) | ||||||
Tax Rate | |||||||||
NOPAT | (23,796) | (18,961) | (18,341) | ||||||
Net income | (25,038) -21.78% | (32,010) 29.04% | (24,806) 30.65% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 23,296 | 810 | (144) | ||||||
BB yield | -8.55% | -0.33% | 0.08% | ||||||
| Debt | |||||||||
Debt current | 6,161 | 43,455 | 28,345 | ||||||
Long-term debt | 55,702 | 14,252 | 19,146 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 8,506 | 2,900 | 3,184 | ||||||
Net debt | 41,966 | 50,786 | 20,169 | ||||||
| Cash flow | |||||||||
Cash from operating activities | (11,922) | (25,421) | (22,393) | ||||||
CAPEX | (324) | (1,027) | (1,974) | ||||||
Cash from investing activities | (613) | 1,254 | (411) | ||||||
Cash from financing activities | 25,528 | 6,016 | 326 | ||||||
FCF | (22,857) | (18,302) | (21,519) | ||||||
| Balance | |||||||||
Cash | 19,460 | 6,467 | 27,177 | ||||||
Long term investments | 437 | 454 | 145 | ||||||
Excess cash | 19,300 | 6,427 | 27,118 | ||||||
Stockholders' equity | (71,838) | (49,963) | (20,535) | ||||||
Invested Capital | 98,481 | 65,146 | 54,808 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 28,420 | 25,188 | 24,865 | ||||||
Price | 9.59 -2.24% | 9.81 32.21% | 7.42 -36.58% | ||||||
Market cap | 272,543 10.30% | 247,099 33.93% | 184,501 -28.47% | ||||||
EV | 314,509 | 329,642 | 229,225 | ||||||
EBITDA | (21,989) | (21,062) | (21,072) | ||||||
EV/EBITDA | |||||||||
Interest | 4,617 | 3,932 | 1,844 | ||||||
Interest/NOPBT | |||||||||